Benefit With No Target: Long-Term Outcomes of Chemoimmunotherapy in "PD-L1 Negative" NSCLC
- PMID: 39111997
- DOI: 10.1016/j.jtho.2024.05.376
Benefit With No Target: Long-Term Outcomes of Chemoimmunotherapy in "PD-L1 Negative" NSCLC
Conflict of interest statement
Disclosure Dr. Perrone reports receiving travel support from Merck Sharp & Dohme and Novartis and having participation on an advisory board of Novartis. Dr. Leonetti reports receiving speakers’ fees from AstraZeneca, Merck Sharp & Dohme, Sanofi, and Takeda; serving on the advisory boards of AstraZeneca, BeiGene, Novartis, and Sanofi; having editorial activities sponsored by Eli Lilly and Roche; and receiving travel support from Merck Sharp & Dohme and Novartis. Dr. Tiseo reports receiving speakers’ and consultants’ fees from AstraZeneca, Pfizer, Eli Lilly, Bristol Myers Squibb, Novartis, Roche, Merck Sharp & Dohme, Boehringer Ingelheim, Takeda, Amgen, Merck, Sanofi, Janssen, and Daiichi Sankyo; institutional research grants from AstraZeneca, Boehringer Ingelheim, and Roche; and travel support from Amgen and Takeda. Dr. Facchinetti reports serving on the advisory board of BeiGene.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials